Single-agent pamidronate for palliative therapy of canine appendicular osteosarcoma bone pain

Journal of Veterinary Internal Medicine

Volumn 21, Issue 3, 2007, Pages 431-439

  Fan, Timothy M ^a   De Lorimier, Louis Philippe ^a   O'Dell Anderson, Kristen ^a   Lacoste, Hugues I ^a   Charney, Sarah C ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Aminobisphosphonate; Bone sarcoma; Dual energy x ray absorptiometry; Malignant osteolysis; Pain alleviation; Urine N telopeptide

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; PAMIDRONIC ACID; PEPTIDE; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL; ANIMAL DISEASE; ARTICLE; BONE DENSITY; BONE TUMOR; DOG; DOG DISEASE; DRUG EFFECT; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; OSTEOSARCOMA; PAIN; PALLIATIVE THERAPY; PROSPECTIVE STUDY; TREATMENT OUTCOME; URINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE DENSITY; BONE NEOPLASMS; COLLAGEN TYPE I; DIPHOSPHONATES; DOG DISEASES; DOGS; FEMALE; INJECTIONS, INTRAVENOUS; MALE; OSTEOSARCOMA; PAIN; PALLIATIVE CARE; PEPTIDES; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

ANIMALIA; CANIS FAMILIARIS;

EID: 34249289683     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2007)21[431:SPFPTO]2.0.CO;2     Document Type: Article

References (33)

1. Chun R, de Lorimier LP. Update on the biology and management of canine osteosarcoma. Vet Clin North Am Small Anim Pract 2003;33:491-516, vi.
2. Goblirsch MJ, Zwolak P, Clohisy DR. Advances in understanding bone cancer pain. J Cell Biochem 2005;96:682-688.
3. Clohisy DR, Mantyh PW. Bone cancer pain. Clin Orthop Relat Res 2003;S279-288.
4. Body JJ, Bartl R, Burckhardt P, et al. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 1998;16:3890-3899.
5. Body JJ, Mancini I. Bisphosphonates for cancer patients: Why, how, and when? Support Care Cancer 2002; 10:399-407.
6. Rogers MJ, Watts DJ, Russell RG. Overview of bisphosphonates. Cancer 1997;80:1652-1660.
7. Rosen HN, Moses AC, Garber J, et al. Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 2000;66:100-103.
8. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer 2000;88:2919-2926.
9. Fontana A, Delmas PD. Markers of bone turnover in bone metastases. Cancer 2000;88:2952-2960.
10. Lipton A, Demers L, Curley E, et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 1998;34:2021-2026.
11. Costa L, Demers LM, Gouveia-Oliveira A, et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 2002;20:850-856.
12. Lacoste H, Fan TM, de Lorimier LP, et al. Urine N-telopeptide excretion in dogs with appendicular osteosarcoma. J Vet Intern Med 2006;20:335-341.
13. Bachrach LK. Dual energy x-ray absorptiometry (DEXA) measurements of bone density and body composition: Promise and pitfalls. J Pediatr Endocrinol Metab 2000;13(Suppl 2):983-988.
14. Kirk JK, Nichols M, Spangler JG. Use of a peripheral dexa measurement for osteoporosis screening. Fam Med 2002;34: 201-205.
15. Berruti A, Dogliotti L, Osella G, et al. Evaluation by dual energy x-ray absorptiometry of changed bone density in metastatic bone sites as a consequence of systemic treatment. Oncol Rep 2000;7:777-781.
16. Tarvainen R, Arnala I, Nevalainen T, et al. Clodronate increases bone mineral density in young growing oophorectomized beagles. Ann Chir Gynaecol 1995;84:304-308.
17. Lauten SD, Cox NR, Brawner WR Jr., et al. Use of dual energy x-ray absorptiometry for noninvasive body composition measurements in clinically normal dogs. Am J Vet Res 2001;62: 1295-1301.
18. Ehrhart N, Eurell JA, Tommasini M, et al. Effect of cisplatin on bone transport osteogenesis in dogs. Am J Vet Res 2002;63:703-711.
19. Fan TM, de Lorimier LP, Charney SC, et al. Evaluation of intravenous pamidronate administration in 33 cancer-bearing dogs with primary or secondary bone involvement. J Vet Intern Med 2005;19:74-80.
20. Allen MJ, Allen LC, Hoffmann WE, et al. Urinary markers of type I collagen degradation in the dog. Res Vet Sci 2000; 69:123-127.
21. Shin KH, Moon SH, Suh JS, et al. Tumor volume change as a predictor of chemotherapeutic response in osteosarcoma. Clin Orthop Relat Res 2000;376:200-208.
22. Conzemius MG, Hill CM, Sammarco JL, et al. Correlation between subjective and objective measures used to determine severity of postoperative pain in dogs. J Am Vet Med Assoc 1997; 210:1619-1622.
23. Firth AM, Haldane SL. Development of a scale to evaluate postoperative pain in dogs. J Am Vet Med Assoc 1999;214: 651-659.
24. Farese JP, Milner R, Thompson MS, et al. Stereotactic radiosurgery for treatment of osteosarcomas involving the distal portions of the limbs in dogs. J Am Vet Med Assoc 2004;225: 1567-1572.
25. Green EM, Adams WM, Forrest LJ. Four fraction palliative radiotherapy for osteosarcoma in 24 dogs. J Am Anim Hosp Assoc 2002;38:445-451.
26. Ramirez O 3rd, Dodge RK, Page RL, et al. Palliative radiotherapy of appendicular osteosarcoma in 95 dogs. Vet Radiol Ultrasound 1999;40:517-522.
27. Mueller F, Poirier V, Melzer K, et al. Palliative radiotherapy with electrons of appendicular osteosarcoma in 54 dogs. In Vivo 2005;19:713-716.
28. Croucher PI, De Hendrik R, Perry MJ, et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003; 18:482-492.
29. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004; 114:623-633.
30. Vincenzi B, Santini D, Dicuonzo G, et al. Zoledronic acidrelated angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 2005;25:144-151.
31. Okada Y, Lorenzo JA, Freeman AM, et al. Prostaglandin G/H synthase-2 is required for maximal formation of osteoclastlike cells in culture. J Clin Invest 2000; 105:823-832.
32. Bauer DC, Orwoll ES, Fox KM, et al. Aspirin and NSAID use in older women: Effect on bone mineral density and fracture risk. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1996; 11:29-35.
33. Lane NE, Bauer DC, Nevitt MC, et al. Aspirin and nonsteroidal antiinflammatory drug use in elderly women: Effects on a marker of bone resorption. The Study of Osteoporotic Fractures Research Group. J Rheumatol 1997;24:1132-1136.